emcardioНеотложная кардиология и кардиоваскулярные рискиEmergency Cardiology and Cardiovascular Risks journal2616-633XБелорусский государственный медицинский университет10.51922/2616-633X.2022.6.2.1582emcardio-92Research ArticleМастер-классMaster-classОбзор новых рекомендаций европейского общества кардиологов по кардиоонкологии 2022 годаOverview of the new 2022 european society of cardiology guidelines on cardio-oncologyСуджаеваО. А.SujayevaV. A.

Минск

Minsk

sujayeva@bk.ruГУ «Республиканский научно-практический центр «Кардиология»State Institution “Republican Scientific and Practical Center of Cardiology”2022230620256215821591Copyright © Суджаева О.А., 20252025Суджаева О.А.Sujayeva V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://emcardio.bsmu.by/jour/article/view/92

В статье представлены основные положения Рекомендаций Европейского общества кардиологов (ESC) по кардиоонкологии, разработанного в сотрудничестве с Европейской гематологической ассоциацией, Европейским обществом терапевтической радиологии и онкологии, Международным обществом кардиоонкологов в 2022 году. Это – первое руководство ESC по кардиоонкологии, содержащее 272 новые рекомендации, что делает документ весьма информативным и объемным. В этой связи в рамках настоящей статьи будут отражены лишь некоторые понятия, определения и направления ведения онокологических пациентов. Подробно будут рассмотрены основные факторы сердечно-сосудистого риска, а также существующие подходы к их оценке у пациентов до начала терапии рака и на этапах динамического наблюдения. Отдельно приведена стратификация риска развития сердечно-сосудистых заболеваний, связанных с терапией рака у различных категорий пациентов.

The article presents the main provisions of the European Society of Cardiology (ESC) Guidelines on Cardio-Oncology, developed in collaboration with the European Hematology Association, the European Society for Therapeutic Radiology and Oncology, the International Society of Cardiac Oncology in 2022. This is the first ESC guidelines on cardio-oncology, with 272 new recommendations, making the document very informative and voluminous. In this regard, within the framework of this article, only some concepts, definitions and directions for managing cancer patients will be reflected. The main factors of cardiovascular risk, as well as existing approaches to their assessment in patients before the start of cancer therapy and at the stages of dynamic observation, will be considered in detail. Separately, cardiovascular risk stratification associated with cancer therapy in various categories of patients is given.

артериальная гипертензияаритмиибиомаркерывыжившие после ракакардиоонкологиякардиотоксичность критериимиокардитраксердечная недостаточностьсердечно-сосудистый рискстратификация сердечно-сосудистого рискатерапия ракаэлектрокардиографияэхокардиографияarterial hypertensionarrhythmiasbiomarkerscancer survivorscardio-oncologycardiotoxicity criteriamyocarditiscancerheart failurecardiovascular riskcardiovascular risk stratificationcancer therapyelectrocardiographyechocardiographyReferencesLyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [electronic resource] // European Heart Journal, 2022, ehac244. Available at: https://doi.org/10.1093/eurheartj/ehac244. (accessed 10.09.2022).Lyon A.R., López-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [electronic resource] // European Heart Journal, 2022, ehac244. Available at: https://doi.org/10.1093/eurheartj/ehac244. (accessed 10.09.2022).Di Lisi D., Madaudo C., Alagna G., Santoro M., Rossetto L., Siragusa S., Novo G. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail, 2022, vol. 9, no. 3, pp. 1914–1919. doi: 10.1002/ehf2.13897.Di Lisi D., Madaudo C., Alagna G., Santoro M., Rossetto L., Siragusa S., Novo G. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail, 2022, vol. 9, no. 3, pp. 1914–1919. doi: 10.1002/ehf2.13897.Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2021, vol. 42, no. 34, pp. 3227–3337.Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2021, vol. 42, no. 34, pp. 3227–3337.Rossello X., Dorresteijn J.A., Janssen A., Lambrinou E., Scherrenberg M., Bonnefoy-Cudraz E., Cobain M,, Piepoli M.F., Visseren F.L., Dendale P. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol, 2019, vol. 26, no. 14, pp. 1534–1544. doi: 10.1177/2047487319846715.Rossello X., Dorresteijn J.A., Janssen A., Lambrinou E., Scherrenberg M., Bonnefoy-Cudraz E., Cobain M,, Piepoli M.F., Visseren F.L., Dendale P. Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol, 2019, vol. 26, no. 14, pp. 1534–1544. doi: 10.1177/2047487319846715.Martín García A., Mitroi C., Mazón Ramos P., García Sanz R., Virizuela J.A., Arenas M., Egocheaga Cabello I., Albert D., Anguita Sánchez M., Arrarte Esteban V.I., Ayala de la Peña F., Bonanand Lozano C., Castro A. et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Rev Esp Cardiol (Engl Ed), 2021, vol. 74, no. 5, pp. 438–448. doi: 10.1016/j.rec.2020.11.020.Martín García A., Mitroi C., Mazón Ramos P., García Sanz R., Virizuela J.A., Arenas M., Egocheaga Cabello I., Albert D., Anguita Sánchez M., Arrarte Esteban V.I., Ayala de la Peña F., Bonanand Lozano C., Castro A. et al. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC. Rev Esp Cardiol (Engl Ed), 2021, vol. 74, no. 5, pp. 438–448. doi: 10.1016/j.rec.2020.11.020.Caro-Codón J., López-Fernández T., Álvarez-Ortega C., Zamora Auñón P., Rodríguez I.R., Gómez Prieto P., Buño Soto A., Canales Albendea M., Albaladejo A., Mediavilla G., Feliu Batlle J., Rodríguez Fraga O., Martínez Monzonis A., González-Costello J. et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol, 2022, vol. 29, no. 6, pp. 859–868. doi: 10.1093/eurjpc/zwaa034.Caro-Codón J., López-Fernández T., Álvarez-Ortega C., Zamora Auñón P., Rodríguez I.R., Gómez Prieto P., Buño Soto A., Canales Albendea M., Albaladejo A., Mediavilla G., Feliu Batlle J., Rodríguez Fraga O., Martínez Monzonis A., González-Costello J. et al. Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol, 2022, vol. 29, no. 6, pp. 859–868. doi: 10.1093/eurjpc/zwaa034.Feijen E.A.M., Leisenring W.M., Stratton K.L., Ness K.K., van der Pal H.J.H., van Dalen E.C., Armstrong G.T., Aune G.J., Green D.M., Hudson M.M., Loonen J., Oeffinger K.C., Robison L.L., Yasui Y., Kremer L.C.M., Chow E.J. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol, 2019, vol. 5, no. 6, pp. 864–871.Feijen E.A.M., Leisenring W.M., Stratton K.L., Ness K.K., van der Pal H.J.H., van Dalen E.C., Armstrong G.T., Aune G.J., Green D.M., Hudson M.M., Loonen J., Oeffinger K.C., Robison L.L., Yasui Y., Kremer L.C.M., Chow E.J. Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity. JAMA Oncol, 2019, vol. 5, no. 6, pp. 864–871.Pareek N., Cevallos J., Moliner P., Shah M., Tan L.L., Chambers V., Baksi A.J., Khattar R.S., Sharma R., Rosen S.D., Lyon A.R. Activity and outcomes of a cardio-oncology service in the United Kingdom– a five-year experience. Eur J Heart Fail, 2018, vol. 20, no. 12, pp. 1721–1731. doi: 10.1002/ejhf.1292.Pareek N., Cevallos J., Moliner P., Shah M., Tan L.L., Chambers V., Baksi A.J., Khattar R.S., Sharma R., Rosen S.D., Lyon A.R. Activity and outcomes of a cardio-oncology service in the United Kingdom– a five-year experience. Eur J Heart Fail, 2018, vol. 20, no. 12, pp. 1721–1731. doi: 10.1002/ejhf.1292.Lyon A.R., Dent S., Stanway S., Earl H., Brezden-Masley C., Cohen-Solal A., Tocchetti C.G., Moslehi J.J., Groarke J.D., Bergler-Klein J., Khoo V., Tan L.L., Anker M.S., von Haehling S., Maack C., Pudil R., Barac A., Thavendiranathan P., Ky B. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society. Eur J Heart Fail, 2020, vol. 22, no. 11, pp. 1945–1960. doi: 10.1002/ejhf.1920.Lyon A.R., Dent S., Stanway S., Earl H., Brezden-Masley C., Cohen-Solal A., Tocchetti C.G., Moslehi J.J., Groarke J.D., Bergler-Klein J., Khoo V., Tan L.L., Anker M.S., von Haehling S., Maack C., Pudil R., Barac A., Thavendiranathan P., Ky B. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society. Eur J Heart Fail, 2020, vol. 22, no. 11, pp. 1945–1960. doi: 10.1002/ejhf.1920.Libby P., Sidlow R., Lin A.E., Gupta D., Jones L.W., Moslehi J., Zeiher A., Jaiswal S., Schulz C., Blankstein R., Bolton K.L., Steensma D., Levine R.L., Ebert B.L. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol, 2019, vol. 74, no. 4, pp. 567–577.Libby P., Sidlow R., Lin A.E., Gupta D., Jones L.W., Moslehi J., Zeiher A., Jaiswal S., Schulz C., Blankstein R., Bolton K.L., Steensma D., Levine R.L., Ebert B.L. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week. J Am Coll Cardiol, 2019, vol. 74, no. 4, pp. 567–577.Garcia-Pavia P., Kim Y., Restrepo-Cordoba M.A., Lunde I.G., Wakimoto H., Smith A.M., Toepfer C.N., Getz K., Gorham J., Patel P., Ito K., Willcox J.A., Arany Z., Li J., Owens A.T., Govind R., Nuñez B., Mazaika E., Bayes-Genis A., Walsh R. et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation, 2019, vol. 140, no. 1, pp. 31–41. doi: 10.1161/CIRCULATIONAHA.118.037934.Garcia-Pavia P., Kim Y., Restrepo-Cordoba M.A., Lunde I.G., Wakimoto H., Smith A.M., Toepfer C.N., Getz K., Gorham J., Patel P., Ito K., Willcox J.A., Arany Z., Li J., Owens A.T., Govind R., Nuñez B., Mazaika E., Bayes-Genis A., Walsh R. et al. Genetic variants associated with cancer therapy-induced cardiomyopathy. Circulation, 2019, vol. 140, no. 1, pp. 31–41. doi: 10.1161/CIRCULATIONAHA.118.037934.Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC CardioOncology, 2020, vol. 2, no. 4, pp. 539–552.Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC CardioOncology, 2020, vol. 2, no. 4, pp. 539–552.Zamorano J.L., Gottfridsson C., Asteggiano R., Atar D., Badimon L., Bax J.J., Cardinale D., Cardone A., Feijen E.A.M., Ferdinandy P., López-Fernández T., Gale C.P., Maduro J.H., Moslehi J., Omland T., Plana Gomez J.C., Scott J., Suter T.M., Minotti G. The cancer patient and cardiology. Eur J Heart Fail, 2020, vol. 22, no. 12, pp. 2290–2309.Zamorano J.L., Gottfridsson C., Asteggiano R., Atar D., Badimon L., Bax J.J., Cardinale D., Cardone A., Feijen E.A.M., Ferdinandy P., López-Fernández T., Gale C.P., Maduro J.H., Moslehi J., Omland T., Plana Gomez J.C., Scott J., Suter T.M., Minotti G. The cancer patient and cardiology. Eur J Heart Fail, 2020, vol. 22, no. 12, pp. 2290–2309.

The authors declare that there are no conflicts of interest present.